| References |
Top |
| REF 1 |
Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat Methods. 2013 Apr;10(4):307-14.
|
| REF 2 |
Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol. 2003 Jul;23(14):4796-804.
|
| REF 3 |
Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs. J Biol Chem. 2003 Apr 25;278(17):14926-35.
|
| REF 4 |
Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J Biol Chem. 1999 Jan 29;274(5):2893-8.
|
| REF 5 |
Creation of a stress-activated p90 ribosomal S6 kinase. The carboxyl-terminal tail of the MAPK-activated protein kinases dictates the signal transduction pathway in which they function. J Biol Chem. 2000 Oct 13;275(41):31588-93.
|
| REF 6 |
90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling. J Biol Chem. 2004 Jul 9;279(28):29325-35.
|
| REF 7 |
Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control. Mol Biol Cell. 2009 May;20(9):2401-12.
|
| REF 8 |
IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J. 1997 Jun 2;16(11):3133-44.
|
| REF 9 |
The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem. 1997 Aug 22;272(34):21281-8.
|
| REF 10 |
All three IkappaB isoforms and most Rel family members are stably associated with the IkappaB kinase 1/2 complex. Eur J Biochem. 1999 Jan;259(1-2):253-61.
|
| REF 11 |
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94.
|
| REF 12 |
Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J. 2005 Jun 15;388(Pt 3):973-84.
|
